Form 13-F position report

CERO THERAPEUTICS HLDGS INC

Reported by Periscope Capital Inc

CEROW CUSIP 71902K113 Manager CIK 0001695320

Reported 427,634 shares, down 163,866 (27.7%) from the prior quarter.

Reported value -78.7%; share count -27.7% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2024
Shares 427,634 Quarter-end amount reported
Reported value $8,595 Fair value at quarter end
Consecutive quarters held 10 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2022-03-31 65000
2022-06-30 32000
2022-09-30 86000
2022-12-31 40600
2023-03-31 38301
2023-06-30 61858
2023-09-30 68528
2023-12-31 25635
2024-03-31 40340
2024-06-30 8595
2024-09-30 2170
2024-12-31 2274
2025-03-31 3973
2025-06-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

14 quarters
Quarterly reported position history for CERO THERAPEUTICS HLDGS INC held by Periscope Capital Inc.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q2 2025 Reduced 0 -274,000 (-100.0%) 0 $0 2025-08-14
Q1 2025 Unchanged 274,000 0 (0.0%) < 0.01% $3,973 2025-05-13
Q4 2024 Reduced 274,000 -151,534 (-35.6%) < 0.01% $2,274 2025-02-10
Q3 2024 Reduced 425,534 -2,100 (-0.5%) < 0.01% $2,170 2024-11-12
Q2 2024 Reduced 427,634 -163,866 (-27.7%) < 0.01% $8,595 2024-08-13
Q1 2024 Reduced 591,500 -365,598 (-38.2%) 0.01% $40,340 2024-05-13
Q4 2023 Unchanged 957,098 0 (0.0%) < 0.01% $25,635 2024-02-13
Q3 2023 Unchanged 957,098 0 (0.0%) < 0.01% $68,528 2023-11-06
Q2 2023 Unchanged 957,098 0 (0.0%) < 0.01% $61,858 2023-08-14
Q1 2023 Unchanged 957,098 0 (0.0%) < 0.01% $38,301 2023-05-12
Q4 2022 Added 957,098 +26,300 (2.8%) < 0.01% $40,600 2023-02-13
Q3 2022 Added 930,798 +630,998 (210.5%) < 0.01% $86,000 2022-11-08
Q2 2022 Unchanged 299,800 0 (0.0%) < 0.01% $32,000 2022-08-15
Q1 2022 New 299,800 +299,800 (0.0%) < 0.01% $65,000 2022-05-16

Who else reported the position

39 managers reported CERO THERAPEUTICS HLDGS INC for Q2 2024.

Managers reporting CERO THERAPEUTICS HLDGS INC in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Atalaya Capital Management LP Reduced 424,867 -133 0.02% $8,497,000 11 qtrs
Context Capital Management LLC Unchanged 122,013 0 < 0.01% $2,452,000 10 qtrs
Silver Rock Financial LP Unchanged 12,224 0 < 0.01% $246,000 7 qtrs
HIGHBRIDGE CAPITAL MANAGEMENT LLC Added 829,598 +1,054 < 0.01% $16,592 11 qtrs
COWEN AND COMPANY LLC Added 687,068 +48,467 < 0.01% $13,810 7 qtrs
CANTOR FITZGERALD L P Unchanged 441,048 0 < 0.01% $8,865 11 qtrs
Periscope Capital Inc This report Reduced 427,634 -163,866 < 0.01% $8,595 10 qtrs
MMCAP International Inc SPC Unchanged 375,000 0 < 0.01% $7,538 11 qtrs
Saba Capital Management L P Unchanged 295,913 0 < 0.01% $5,948 11 qtrs
Linden Advisors LP Unchanged 249,999 0 < 0.01% $5,625 10 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 13, 2024
Filing type
13F-HR
Position type
*W EXP 02/13/202

Voting authority reported

Sole
0
Shared
0
None
427,634

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.